At Riverside, we put our patients’ health and well-being first. Our research team demonstrates this priority through our clinical trials by engaging in research that advances lifelong learning and evidence-based improvements in patient care. Currently, we have a range of ongoing clinical trials in Cardiology, Neurology, and Oncology. Our principal investigators have countless years of experience in study and research.
We are currently recruiting for the following clinical trials:
Cardiology
- BENEFITS OF MICROCOR (?COR™) IN AMBULATORY DECOMPENSATED HEART FAILURE (BMAD-HF)
- EMPACT-MI: A streamlined, multicentre, randomised, parallel group, double-blind placebo-controlled superiority trial to evaluate the effect of EMPAgliflozin on hospitalisation for heart failure and mortality in patients with aCuTe Myocardial Infarction
- HEART-FID - A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency
Oncology
- A Survey and Registry Study of Patient Perceptions and Experiences with Oral Chemotherapy at a Community Hospital.
- An Observational Study of Triple Negative Breast Cancer at a Community Hospital
- Astra Zeneca D3614C00001 - A Phase III Double-blind Randomized Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First-Line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer
- Celgene ACE-536-MDS-002: A phase 3, open-label, randomized study to compare the efficacy and safety of Luspatercept (ACE-536) versus Epoetin Alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk myelodysplastic syndromes (MDS) in ESA naive subjects who require red blood cell transfusions. (COMMANDS)
- “Connect” The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
- Oral Chemo Financial Study #012019 - A Survey and Registry Study of the Cost Coverage and Financial Impact Upon Patients of Targeted Oral Anti-Cancer Medications at a Community Hospital Network
- A011801 The COMPASSHER2 Residual Disease Trial A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
- ATOMIC A021502 “A Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
- SOLARIS A021703 A Randomized, Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer
- DCP-001: Use of a Clinical Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Related: